Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Shares Rose 61.7% in April

By Adria Cimino – May 4, 2020 at 11:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Inovio shares climbed as the company’s coronavirus vaccine entered clinical trials.

What happened

Inovio Pharmaceuticals (INO -2.79%) shares soared 61.7% in April, according to data provided by S&P Global Market Intelligence, as the company began human trials of its coronavirus vaccine.

A researcher notes clinical trial data on a clipboard while a patient watches in the background.

Image source: Getty Images.

Inovio started a phase 1 trial of its DNA vaccine for COVID-19, the illness caused by the novel coronavirus, early in April and completed enrollment of 40 healthy adults later in the month. The clinical stage company also said it expanded its agreement with Richter-Helm BioLogics GmbH & Co. of Germany to cover large-scale manufacturing of the vaccine. A grant of $1.3 million from the Coalition for Epidemic Preparedness Innovations will partially fund the manufacturing effort.

Inovio's investigational vaccines use optimized DNA plasmids. Through computer sequencing, these small circles of DNA are reorganized to produce a specific immune response in the body. Inovio then delivers these plasmids intradermally or intramuscularly through the company's own handheld smart device.

So what

The move into human testing is a big step for any of the players in this race to find a COVID-19 vaccine. Inovio is among the first of its peers to enter human trials. For this reason investors are optimistic the company may also be among the first to market -- if trial data is favorable.

Considering the extent of the coronavirus outbreak, with cases now topping 3.4 million worldwide, the first few companies to market with a vaccine or treatment are likely to make headlines. And along the way, share gains may continue.

Now what

Inovio said it expects interim safety and immune response data from the phase 1 trial in late June. Depending on that data, the company hopes to begin a phase 2/3 study this summer. Inovio said that it is on target to produce 1 million doses of its vaccine by the end of the year for further studies or emergency use. But Inovio said delivery of the doses will depend on external funding and guidance from the U.S. Food and Drug Administration.

Investors could expect further gains from Inovio with positive news on the COVID-19 vaccine program. But it's unclear if this company -- which doesn't have products on the market so far -- can maintain share gains well into the future.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
INO
$1.74 (-2.79%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.